News
MDNAF
0.267
-9.43%
-0.028
Weekly Report: what happened at MDNAF last week (1102-1106)?
Weekly Report · 5d ago
Weekly Report: what happened at MDNAF last week (1026-1030)?
Weekly Report · 11/02 09:54
Medicenna’s MDNA209 Shows Strong CD122 Blockade and Survival Gains in Autoimmune Preclinical Models
TipRanks · 10/26 13:08
Weekly Report: what happened at MDNAF last week (1019-1023)?
Weekly Report · 10/26 09:54
Medicenna to Showcase CD122 Superantagonist MDNA209 Data at Paris Immunotherapy Meeting
TipRanks · 10/22 13:38
Weekly Report: what happened at MDNAF last week (1012-1016)?
Weekly Report · 10/19 09:54
Weekly Report: what happened at MDNAF last week (1005-1009)?
Weekly Report · 10/12 09:58
Weekly Report: what happened at MDNAF last week (0928-1002)?
Weekly Report · 10/05 09:57
Medicenna Shareholders Back Board, Auditor and Potential Share Consolidation Plan
TipRanks · 10/01 23:32
Medicenna Announces Results of Annual General and Special Meeting of Shareholders
Barchart · 10/01 18:00
Weekly Report: what happened at MDNAF last week (0921-0925)?
Weekly Report · 09/28 09:54
Medicenna to Present New Bizaxofusp Survival Data in Recurrent Glioblastoma at SNO 2026
TipRanks · 09/24 11:41
Weekly Report: what happened at MDNAF last week (0914-0918)?
Weekly Report · 09/21 09:54
Weekly Report: what happened at MDNAF last week (0907-0911)?
Weekly Report · 09/14 09:58
Weekly Report: what happened at MDNAF last week (0831-0904)?
Weekly Report · 09/07 09:53
Medicenna to Spotlight Superkine Pipeline at H.C. Wainwright Global Investment Conference
TipRanks · 09/03 11:41
Weekly Report: what happened at MDNAF last week (0824-0828)?
Weekly Report · 08/31 09:58
Weekly Report: what happened at MDNAF last week (0817-0821)?
Weekly Report · 08/24 09:59
Weekly Report: what happened at MDNAF last week (0810-0814)?
Weekly Report · 08/17 10:00
Medicenna Therapeutics Corp. GAAP EPS of -$0.06
Seeking Alpha · 08/14 14:18
More
Webull provides a variety of real-time MDNAF stock news. You can receive the latest news about Medicenna Therapeutics Corp through multiple platforms. This information may help you make smarter investment decisions.
About MDNAF
Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.